October 10, 2026
- Final Guidance: Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers
October 8, 2026
- FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
This report displays final approvals and tentative approvals of original and supplemental applications for the two days beginning on the earliest date listed below. Some approvals may be added to the Drugs@FDA database after this time span. For comprehensive approval reports, please use the monthly "All Approvals" report on Drugs@FDA.
